virtual-screening
(4)
TandemAI puts the lab inside the loop
A molecule can look magnificent on a screen and disappoint in a flask. TandemAI connects AI, molecular physics and wet labs so the next design can learn from the last experiment.
The Pocket That Wasn't There a Moment Ago
Deep Apple bets that the best drug target may be a fleeting shape of a protein. Its search through billions of virtual molecules has yielded a Novo Nordisk partnership and an early drug candidate - with the hardest tests still ahead.
Numerion Labs
Numerion Labs (formerly Atomwise) is an AI-native drug discovery company that pioneered the use of deep learning for structure-based drug design. Its AI chemistry superplatform - built on the COSMOS foundation model, the APEX hyper-scalable enumerator, and EXPO optimization algorithms - explores billions of drug-like molecules to find and optimize novel chemical matter. Based in San Francisco with a San Diego presence, the company is advancing its own pipeline of small-molecule programs in immune and inflammatory disease while collaborating with partners across the pharmaceutical industry.
Steve Worland
Steve Worland, Ph.D., is the CEO of Numerion Labs, the AI-native drug discovery company that grew out of Atomwise. A medicinal-chemistry lifer with three decades behind him, his bench work fed the discovery of Paxlovid and Inlyta, and his operating record runs from Agouron through a Roche acquisition to a SPAC. Now he is betting that deep-learning surrogates plus GPU enumeration can search billions of molecules in seconds.